The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Natural Course of Crohn's Disease and Novel Treatment Drugs

크론병의 자연경과 및 최신 치료약제

  • Lee, Jin Ha (Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine) ;
  • Cheon, Jae Hee (Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine)
  • 이진하 (연세대학교 의과대학 내과학교실) ;
  • 천재희 (연세대학교 의과대학 내과학교실)
  • Published : 2013.12.01
⟨ Previous Next ⟩

Abstract

Crohn's disease is a chronic recurrent inflammatory disease, mainly affecting the gastrointestinal tract. The pathogenesis of inflammatory bowel disease is believed to be caused by the complex interplay of many factors including host genetic susceptibility, the external environment such as infectious agents or the commensal enteric flora, and the immune system dysfunction. Advances in the understanding of the pathophysiology of inflammatory bowel disease have resulted in the development of multiple biological agents that all represent an alternative to the use of current therapies in patients with refractory Crohn's disease. Moreover, these biologic agents are expected to change the natural course of inflammatory bowel disease. Among them, anti-tumor necrosis factor (TNF)-${\alpha}$ agent is the first developed drug, and it dramatically improved the IBD management. However, more than one-third of the patients do not respond to the drugs due to antibody formation and loss of response. To increase treatment efficacy, enormous efforts have been made to develop novel anti-cytokines which can be an alternative to anti-TNF-${\alpha}$ agents. They are anti-CD4+ T cell cytokines including interleukin (IL)-12/23, IL-17A, and IFN-${\gamma}$ blockers, selective anti-adhesion molecules, anti-inflammatory cytokine IL-10, and immune stimulators. This paper reviews the natural history of Crohn's disease, natural course modifiers, and the efficacy and safety of biologic agents other than anti-TNF ${\alpha}$ agents.

Keywords

References

  1. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in populationbased cohorts. Am J Gastroenterol 2010;105:289-297. https://doi.org/10.1038/ajg.2009.579
  2. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID Study. Inflamm Bowel Dis 2008;14:542-549. https://doi.org/10.1002/ibd.20310
  3. Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008;103:3167-3182. https://doi.org/10.1111/j.1572-0241.2008.02158.x
  4. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-1640. https://doi.org/10.1016/S0140-6736(07)60750-8
  5. Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010;45:571-583. https://doi.org/10.1007/s00535-010-0219-3
  6. Kornbluth A. Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis 1998;4:328-329. https://doi.org/10.1097/00054725-199811000-00014
  7. Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs 2010;24(Suppl 1):3-14. https://doi.org/10.2165/11586290-000000000-00000
  8. Peyrin-Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:870-879. https://doi.org/10.1111/j.1365-2036.2011.04599.x
  9. Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut 2011;60:1178-1181. https://doi.org/10.1136/gut.2010.234617
  10. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-782. https://doi.org/10.1136/gut.49.6.777
  11. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8:244-250. https://doi.org/10.1097/00054725-200207000-00002
  12. Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease: experience with 1379 patients. Ann Surg 1991;214:230-238. https://doi.org/10.1097/00000658-199109000-00006
  13. Greenstein AJ, Lachman P, Sachar DB, et al. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 1988;29:588-592. https://doi.org/10.1136/gut.29.5.588
  14. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-678. https://doi.org/10.1136/gut.37.5.674
  15. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119:895-902. https://doi.org/10.1053/gast.2000.18144
  16. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549. https://doi.org/10.1016/S0140-6736(02)08512-4
  17. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-885. https://doi.org/10.1056/NEJMoa030815
  18. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009;136:441-450.e1. https://doi.org/10.1053/j.gastro.2008.10.051
  19. D'haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European Multicenter Trial. Gastroenterology 1999;116:1029-1034. https://doi.org/10.1016/S0016-5085(99)70005-3
  20. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM Study. Gastroenterology 2008;135:1493-1499. https://doi.org/10.1053/j.gastro.2008.07.069
  21. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012;61:918-932. https://doi.org/10.1136/gutjnl-2011-300904
  22. Fuss IJ, Becker C, Yang Z, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. 2006;12:9-15. https://doi.org/10.1097/01.MIB.0000194183.92671.b6
  23. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-852. https://doi.org/10.1146/annurev.immunol.25.022106.141557
  24. MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 2011;140:1768-1775. https://doi.org/10.1053/j.gastro.2011.02.047
  25. Semerano L, Assier E, Delavallée L, Boissier MC. Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Expert Opin Biol Ther 2011;11:545-550. https://doi.org/10.1517/14712598.2011.566856
  26. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. 2008;135:1130-1141.
  27. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351: 2069-2079. https://doi.org/10.1056/NEJMoa033402
  28. Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006;55:1138-1144.
  29. Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55:1131-1137.
  30. Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010;16:233-242. https://doi.org/10.1002/ibd.21038
  31. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION Study. Ann Rheum Dis 2010;69:88-96. https://doi.org/10.1136/ard.2008.105197
  32. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20:222-232. https://doi.org/10.3109/s10165-010-0279-5
  33. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-996. https://doi.org/10.1053/j.gastro.2004.01.012
  34. Berg DJ, Davidson N, Kühn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996;98:1010-1020. https://doi.org/10.1172/JCI118861
  35. Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease: Crohn's Disease Study Group. Gastroenterology 1997; 113:383-389. https://doi.org/10.1053/gast.1997.v113.pm9247454
  36. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease: the Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000;119:1473-1482. https://doi.org/10.1053/gast.2000.20229
  37. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease: Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000;119:1461-1472. https://doi.org/10.1053/gast.2000.20196
  38. Colombel JF, Rutgeerts P, Malchow H, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001;49:42-46. https://doi.org/10.1136/gut.49.1.42
  39. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4:754-759. https://doi.org/10.1016/j.cgh.2006.03.028
  40. Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117:58-64. https://doi.org/10.1016/S0016-5085(99)70550-0
  41. Sands BE, Winston BD, Salzberg B, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002; 16:399-406. https://doi.org/10.1046/j.1365-2036.2002.01179.x
  42. Herrlinger KR, Witthoeft T, Raedler A, et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 2006;101:793-797. https://doi.org/10.1111/j.1572-0241.2005.00356.x
  43. Pena Rossi C, Hanauer SB, Tomasevic R, Hunter JO, Shafran I, Graffner H. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol 2009;9:22. https://doi.org/10.1186/1471-230X-9-22
  44. Kim KO, Jang BI. Emerging drugs in the treatment of inflammatory bowel disease: beyond anti-TNF-$\alpha$. Korean J Gastroenterol 2011;58:235-244. https://doi.org/10.4166/kjg.2011.58.5.235
  45. Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006;367:668-678. https://doi.org/10.1016/S0140-6736(06)68265-2
  46. Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009;206:1883-1897. https://doi.org/10.1084/jem.20091233
  47. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-606. https://doi.org/10.1038/35079114
  48. Dejaco C, Lichtenberger C, Miehsler W, et al. An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion 2003;68:63-70. https://doi.org/10.1159/000074517
  49. Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther 2005;21: 391-400. https://doi.org/10.1111/j.1365-2036.2005.02287.x
  50. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002;360:1478-1480. https://doi.org/10.1016/S0140-6736(02)11437-1
  51. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ; Sargramostim in Crohn's Disease Study Group. Sargramostim for active Crohn's disease. N Engl J Med 2005;352:2193-2201. https://doi.org/10.1056/NEJMoa041109
  52. Valentine JF, Fedorak RN, Feagan B, et al. Steroid-sparing properties of sargramostim in patients with corticosteroid- dependent Crohn's disease: a randomised, double-blind, placebo- controlled, phase 2 study. Gut 2009;58:1354-1362. https://doi.org/10.1136/gut.2008.165738
  53. Kelsen JR, Rosh J, Heyman M, et al. Phase I trial of sargramostim in pediatric Crohn's disease. Inflamm Bowel Dis 2010;16:1203-1208. https://doi.org/10.1002/ibd.21204
  54. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo- controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-274. https://doi.org/10.1053/gast.2001.26260
  55. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-1683. https://doi.org/10.1053/j.gastro.2007.03.024
  56. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-659. https://doi.org/10.1038/ajg.2011.73
  57. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381. https://doi.org/10.1056/NEJMoa051847
  58. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6: 1370-1377. https://doi.org/10.1016/j.cgh.2008.06.007
  59. Shanahan WR Jr. ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1. Expert opin Investig Drugs 1999;8:1417-1429. https://doi.org/10.1517/13543784.8.9.1417
  60. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114: 1133-1142. https://doi.org/10.1016/S0016-5085(98)70418-4
  61. Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001;120:1339-1346. https://doi.org/10.1053/gast.2001.24015
  62. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-36. https://doi.org/10.1136/gut.51.1.30